ECOR electroCore Inc

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the first quarter ended March 31, 2022, after the close of the market on Thursday, May 5, 2022. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions.Thursday, May 5, 2022, 4:30 PM EDTDomestic: 877-269-7756International: 201-689-7817Conference ID: 13728177 Webcast: electroCore Earnings Webcast

About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.For more information, visit www.electrocore.com. 

Contact:Rich CockrellCG Capital404-736-3838ecor@cg.capital